This study also revealed that <i>TWIST1</i> facilitates EMT and enhances malignant potential by promoting tumor migration, invasion, and cisplatin chemoresistance through the <i>TWIST1-TGFBI-ZEB1</i> axis in ESCC, highlighting the prognostic and therapeutic potential of <i>TWIST1</i> in clinical ESCC treatment. The gene discussed is ZEB1; the disease is neoplasm.